Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...